Immediate birth for women between 34 and 37 weeks of gestation with prolonged preterm prelabour rupture of membranes and detection of vaginal or urine group B streptococcus: an economic evaluation-Reference-Cited by-同舟云学术

Immediate birth for women between 34 and 37 weeks of gestation with prolonged preterm prelabour rupture of membranes and detection of vaginal or urine group B streptococcus: an economic evaluation

Published:2022-03-08 Issue:10 Volume:129 Page:1779-1789
ISSN:1470-0328
Container-title:BJOG: An International Journal of Obstetrics & Gynaecology
language:en
Short-container-title:BJOG

Author:

Dietz Jeremy¹,Plumb Jane²,Banfield Philip³,Soe Aung⁴,Chehadah Fadi⁵,Chang‐Douglass Stacey¹,Rogers Gabriel⁶

Affiliation:

1. Centre for Guidelines National Institute for Health and Care Excellence (NICE) London UK

2. Group B Strep Support Haywards Heath West Sussex UK

3. Glan Clwyd Hospital Bodelwyddan Rhyl UK

4. Oliver Fisher Neonatal Unit Medway Maritime Hospital Gillingham Kent UK

5. Centre for Guidelines National Institute for Health and Care Excellence (NICE) Manchester UK

6. Division of Population Health, Manchester Centre for Health Economics The University of Manchester Manchester UK

Funder

National Institute for Health and Care Excellence

Publisher

Wiley

Subject

Obstetrics and Gynecology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1471-0528.17119

Reference41 articles.

1. Maternal morbidity and perinatal outcome in preterm premature rupture of membranes before 37 weeks gestation;Dars S;Pakistan J Med Sci,2014

2. Care of Women Presenting with Suspected Preterm Prelabour Rupture of Membranes from 24 +0 Weeks of Gestation

3. Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks' gestation for improving pregnancy outcome

4. Neonatal infections in England: the NeonIN surveillance network

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses;PharmacoEconomics;2024-05-31